Repurposed Cancer Treatments
Off-patent drugs with anticancer evidence. Each gets an evidence grade based on the quality of human clinical data, not preclinical hype.
Mebendazole for Lung Cancer
Phase I/II data in small cell lung cancer. Microtubule disruption mechanism, crosses blood-brain barrier.
🔬 Grade B: PromisingItraconazole for Lung Cancer
Phase II trial in NSCLC showing 72-79% tumor growth reduction in xenograft models. Hedgehog + VEGFR2 pathway inhibition.
🔬 Grade B: PromisingDisulfiram (Antabuse) + Copper for Cancer
Phase II trials in GBM, breast, and pancreatic cancer. Cuproptosis mechanism discovered in 2022. Cancer stem cell elimination.
🔬 Grade B: PromisingThe Press-Pulse Protocol
Thomas Seyfried's metabolic framework targets both glucose and glutamine simultaneously. The most complete dietary-metabolic approach to cancer management.
🔬 Grade B: PromisingHigh-Dose IV Vitamin C: The Trial That Doubled Survival
A Phase II RCT doubled overall survival in metastatic pancreatic cancer. We break down the Iowa trial, mechanism, and what it means.
⭐ Grade A: Strong EvidenceMebendazole: The $5 Cancer Drug
An FDA-approved dewormer with Phase I/II trial data in glioblastoma and colorectal cancer. Crosses the blood-brain barrier.
🔬 Grade B: PromisingQuercetin for Cancer
Senolytic flavonoid that clears chemotherapy-induced senescent cells. D+Q combination in early human trials. Low oral bioavailability remains a problem.
🔶 Grade C: Early / LimitedMistletoe (Iscador) for Cancer
Used in German integrative oncology for decades. Quality of life benefits documented in RCTs. Survival benefit unproven but cohort studies are intriguing.
🔶 Grade C: Early / LimitedCBD Oil for Cancer
Cannabidiol shows apoptosis, angiogenesis inhibition, and metastasis suppression in lab models. Human evidence is anecdotal. Grade C.
🔶 Grade C: Early / LimitedTurkey Tail Mushroom and Cancer
PSK (polysaccharide-K) approved as cancer adjuvant in Japan since 1977. Cochrane review found significant survival benefit in GI cancers with chemotherapy.
🔬 Grade B: PromisingArtemisinin for Cancer
Iron-dependent oxidative stress selectively toxic to cancer cells. Phase I/II trials show safety and early signal. One of the most compelling off-patent compounds.
🔬 Grade B: Promising